Lack of association between a polymorphism in the promoter region of the dopamine-2 receptor gene and clozapine response

Pharmacogenetics

Volumn 8, Issue 6, 1998, Pages 481-484

  Arranz, Maria J ^a   Li, Tao ^a   Munro, J ^a   Liu, X ^a   Murray, Robin ^a   Collier, David A ^a   Kerwin, R W ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Antipsychotic response; Clozapine; Dopamine

Indexed keywords

CLOZAPINE; DOPAMINE 2 RECEPTOR; NEUROLEPTIC AGENT;

ARTICLE; CAUCASIAN; CHINESE; CONTROLLED STUDY; DRUG EFFICACY; DRUG RECEPTOR BINDING; GENETIC POLYMORPHISM; GENETIC VARIABILITY; HUMAN; LIMBIC SYSTEM; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; RECEPTOR GENE; SCHIZOPHRENIA; CASE CONTROL STUDY; CHINA; ETHNOLOGY; GENETICS;

ANTIPSYCHOTIC AGENTS; CASE-CONTROL STUDIES; CHINA; CLOZAPINE; HUMANS; POLYMORPHISM, GENETIC; PROMOTER REGIONS (GENETICS); RECEPTORS, DOPAMINE D2; SCHIZOPHRENIA;

EID: 0032217288     PISSN: 0960314X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008571-199812000-00004     Document Type: Article

References (12)

1. Arinami T, Gao M, Hamaguchi H, Toru M. A functional polymorphism in the promoter region of the dopamine D2 receptor gene is associated with schizophrenia. Hum Mol Genetics 1997; 6:577-582.
2. Arranz M, Collier D, Sodhi M, Ball D, Roberts G, Price J, et al. Association between clozapine response and allelic variation in 5-HT2A receptor gene. Lancet 1995; 346:281-282.
3. Arranz MJ, Munro J, Owen MJ, Spurlock G, Sham P, Zhao J, et al. Evidence for association between polymorphisms in the promoter and coding regions of the 5-HT2A receptor gene and response to clozapine. Mol Psychiatry 1998; 3:61-66.
4. Li T, Arranz MJ, Aitchison KJ, Bryant C, Liu X, Kerwin RW, et al. Case-control, haplotype relative risk and transmission disequilibrium analysis of a dopamine D2 receptor functional promoter polymorphism in schizophrenia. Schizophr Res 1998; 32:87-92.
5. McGuffin P, Owen MJ, Farmer AE. Genetic basis of schizophrenia. Lancet 1995; 346:678-682.
6. Pilowsky L, Mulligan R, Acton PD, Ell PJ, Costa DC, Kerwin RW. Limbic selectivity of clozapine. Lancet 1997; 350:490-491.
7. Rietschel M, Naber D, Oberlander H, Holzback R, Fimmers R, Eggermann K, et al. Efficacy and side-effects of clozapine: testing for association with allelic variation in the dopamine D4 receptor gene. Neuropsychopharmacolgy 1996; 15:491-496.
8. Sanyal S, Van Tol HH. Review of the role of dopamine in schizophrenia and antipsychotic action. J Psychiatr Res 1997; 31: 219-232.
9. Seeman P, Guan HC, Nobrega J, Jiwa D, Markstein R, Balk JH, et al. Dopamine D2-like sites in schizophrenia, but not in Alzheimer's. Huntington's, or control brains, for [3H] benzquinoline. Synapse 1997; 25:137-146.
10. Shaikh S, Collier D, Arranz M, Ball D, Gill M, Kerwin R. DRD2 Ser 311/Cys311 polymorphism in schizophrenia. Lancet 1994; 343:1045-1046.
11. Shaikh S, Collier D, Sham P, Pilowsky L, Sharma T, Lin L, et al. Analysis of clozapine response and polymorphisms of the dopamine D4 receptor gene (DRD4) in schizophrenic patients. Am J Med Genetics 1995; 60:541-545.
12. 2α receptor gene. Neuroreport 1995; 7:169-172.